HUMANA INC 8-K

What Happened

• Humana Inc. filed a Form 8‑K dated June 1, 2026 disclosing senior management will meet with investors and analysts between June 1 and June 30, 2026 and will reaffirm its FY 2026 earnings guidance. The Company reiterated GAAP diluted EPS guidance of at least $8.36 and adjusted (non‑GAAP) EPS guidance of at least $9.00 for the year ending Dec. 31, 2026.
• The filing provides a reconciliation from GAAP to adjusted EPS: +$0.30 for amortization of identifiable intangibles, -$0.28 for put/call valuation adjustments on certain minority investments, +$0.81 for value creation initiatives, and -$0.19 for cumulative net tax impact, producing the at least $9.00 adjusted EPS projection. The company noted the guidance excludes the impact of value changes not yet recognized or reasonably estimable.

Key Details

• Filing date: June 1, 2026; meetings scheduled June 1–30, 2026 (senior management with investors/analysts).
• FY 2026 guidance: GAAP diluted EPS ≥ $8.36; Adjusted (non‑GAAP) EPS ≥ $9.00.
• Reconciliation items (per share): amortization +$0.30; put/call adjustments -$0.28; value creation initiatives +$0.81; tax impact -$0.19.
• Company does not expect changes to FY 2026 adjusted EPS guidance but may update GAAP EPS guidance as value creation and strategic initiatives progress.

Why It Matters

• For investors, the reaffirmation gives clarity on Humana’s expected earnings for FY 2026 and signals management’s current confidence in meeting its adjusted earnings target. Adjusted (non‑GAAP) EPS is used by management to track core operating performance and for incentive compensation, so the $9.00 target is a key metric for performance assessment.
• The filing also warns that GAAP EPS could change as the company recognizes value changes from strategic initiatives, and includes the standard forward‑looking statement caution — meaning outcomes can still be affected by risks and uncertainties disclosed in Humana’s SEC filings.